Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Brief Summary: This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer (NSCLC).

The primary hypotheses are that treatment with pembrolizumab prolongs: 1) Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor compared to placebo, and 2) Overall Survival (OS).

After analysis of interim results was conducted, the protocol was amended (Amendment 5) to allow participants the option to discontinue placebo in the control arm and to switch to pembrolizumab in the event of documented progressive disease as assessed by central review.


Options:
A: Arm Label: Arm A (Atezolizumab+Paclitaxel+Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Bevacizumab, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm C (Bevacizumab+Paclitaxel+Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin)
B: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy
C: Arm Label: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: B